ALDEYRA THERAPEUTICS INC (ALDX)

US01438T1060 - Common Stock

6.11  -0.04 (-0.65%)

After market: 6.11 0 (0%)

ALDEYRA THERAPEUTICS INC

NASDAQ:ALDX (9/27/2023, 7:11:09 PM)

After market: 6.11 0 (0%)

6.11

-0.04 (-0.65%)

Chartmill TA Rating
Chartmill Setup Rating
Sector
GICS SectorHealth Care
GICS IndustryBiotechnology
Chartmill FA Rating
Valuation
Growth
Profitability
Health
Dividend
Overview
Earnings (Last)08-03 2023-08-03/amc
Earnings (Next)11-08 2023-11-08/bmo
Ins Owners2.92%
Inst Owners66.6%
Market Cap358.02M
Shares58.60M
PEN/A
Fwd PEN/A
Dividend YieldN/A
Analysts88.57
IPO05-02 2014-05-02
Stock Screener Links
Screen Image

Nasdaq Stock Screener

Find more stocks on Nasdaq

Screen Image

USA Stock Screener

Find more stocks on the USA

Screen Image

GICS Sector Stock Screener

Find competitors from the same sector on the USA

Screen Image

GICS Industry Stock Screener

Find competitors from the same industry on the USA

Screen Image

Technical Stock Screener

Find stocks with similar TA and Setup ratings on the USA

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Technical Competitors Stock Screener

Find the competitors with the best technical ratings on the USA

Screen Image

Best Technical Setups Competitors Stock Screener

Find the competitors with the best technical and setup ratings on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA

Screen Image

Best Analyst Rating Competitors Stock Screener

Find the competitors with the best analyst ratings on the USA

ALDX Daily chart

Company Profile

Aldeyra Therapeutics, Inc. is a biotechnology company, which engages in research and development activities with related general business planning, including raising capital. The company is headquartered in Lexington, Massachusetts and currently employs 15 full-time employees. The company went IPO on 2014-05-02. The firm's product candidates include reactive aldehyde species (RASP) modulators ADX-629, ADX-246, ADX-248, and chemically related molecules for the treatment of systemic and retinal immune-mediated diseases. Its pre-commercial product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the treatment of primary vitreoretinal lymphoma, proliferative vitreoretinopathy, and other rare sight-threatening retinal diseases. Its ADX-629, is an orally administered RASP modulator in clinical development for atopic dermatitis, idiopathic nephrotic syndrome, moderate alcohol-associated hepatitis, chronic cough, and Sjogren-Larsson Syndrome. Its ADX-246 and ADX-248, for geographic atrophy and systemic inflammatory diseases.

Company Info

ALDEYRA THERAPEUTICS INC

131 Hartwell Avenue, Suite 320

Lexington MASSACHUSETTS 02421

P: 17817614904.0

CEO: Todd C. Brady

Employees: 15

Website: https://www.aldeyra.com/

ALDX News

News Image4 hours ago - Bragar Eagel & Squire, P.C.ALDEYRA DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Aldeyra Therapeutics, Inc. and Encourages Investors to Contact the Firm
News Imagea day ago - Bronstein, Gewirtz & Grossman, LLCFinal Deadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit

/PRNewswire/ -- Attorney Advertising-- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has...

News Image2 days ago - Bronstein, Gewirtz & Grossman, LLCDeadline Alert: ALDX Investor Alert: Contact Bronstein, Gewirtz & Grossman, LLC to Actively Participate in the Aldeyra Therapeutics, Inc. Class Action Lawsuit
News Image2 days ago - SBWireNASDAQ: ALDX Investor Alert: Deadline on September 29, 2023 in Lawsuit Against Aldeyra Therapeutics, Inc.

San Diego, CA -- (SBWIRE) -- 09/25/2023 -- The Shareholders Foundation announced that a deadline is coming up on September 29, 2023 in the lawsuit filed for certain investors of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX).

News Image3 days ago - The Rosen Law Firm PAALDX DEADLINE ALERT: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action – ALDX
News Image4 days ago - THE ROSEN LAW FIRM, P. A.ALDX FINAL DEADLINE ALERT: ROSEN, SKILLED INVESTOR COUNSEL, Encourages Aldeyra Therapeutics, Inc. Investors to Secure Counsel Before Important September 29 Deadline in Securities Class Action - ALDX

/PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) between...

ALDX Twits

Here you can normally see the latest stock twits on ALDX, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.

Example Twits:

Twits example